Literature DB >> 22138027

Varicella zoster vs. herpes simplex meningoencephalitis in the PCR era. A single center study.

Lea Pollak1, Sarah Dovrat, Mazal Book, Ella Mendelson, Miriam Weinberger.   

Abstract

BACKGROUND: The introduction of polymerase chain reaction (PCR) for the diagnosis of herpesvirus central nervous system infections is reshaping our understanding of these illnesses. Varicella-zoster virus (VZV) is increasingly recognized as an important etiology of sporadic viral meningoencephalitis (ME). Furthermore, mild cases of herpes simplex virus (HSV) ME, traditionally considered a devastating infection, are frequently reported.
METHODS: We compared the demographic and clinical features of patients with VZV (20) and HSV (17) ME diagnosed by Real-Time PCR of cerebrospinal samples in a single center during the years 2002-2010.
RESULTS: VZV and HSV patients were comparable with respect to age, sex, underlying diseases, immune suppression, and the rates of fever, headache and altered mental status on presentation. Seizures, focal neurological signs, systemic complications and in-hospital death were noted only in the HSV group.
CONCLUSIONS: Our study confirms the prevalence of VZV as a cause of sporadic ME over the last decade. While patients with HSV ME had more manifestations of severe disease, there also was a significant overlap with clinical and laboratory parameters of VZV ME. In the absence of dermatomal rash, differentiation between VZV and HSV ME on clinical grounds alone may represent a true challenge.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22138027     DOI: 10.1016/j.jns.2011.11.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

1.  Herpes simplex and varicella zoster CNS infections: clinical presentations, treatments and outcomes.

Authors:  Quanhathai Kaewpoowat; Lucrecia Salazar; Elizabeth Aguilera; Susan H Wootton; Rodrigo Hasbun
Journal:  Infection       Date:  2015-12-17       Impact factor: 3.553

2.  Characteristics and outcome of varicella-zoster virus central nervous system infections in adults.

Authors:  A Le Bot; A Ballerie; C Pronier; F Bénézit; F Reizine; M Tas; P Jégo; M Revest; Y Le Tulzo; P Fillâtre; Pierre Tattevin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-28       Impact factor: 3.267

3.  Varicella Zoster Virus Infection of the Central Nervous System - 10 Year Experience from a Tertiary Hospital in South India.

Authors:  Ronald Albert Benton Carey; Vignesh Kumar Chandiraseharan; Anitha Jasper; Tunny Sebastian; Chrusolitha Gujjarlamudi; Sowmya Sathyendra; Anand Zachariah; Asha Mary Abraham; Thambu David Sudarsanam
Journal:  Ann Indian Acad Neurol       Date:  2017 Apr-Jun       Impact factor: 1.383

4.  Herpes simplex viruses (1 and 2) and varicella-zoster virus infections in an adult population with aseptic meningitis or encephalitis: A nine-year retrospective clinical study.

Authors:  Gha-Hyun Lee; Jiyoung Kim; Hyun-Woo Kim; Jae Wook Cho
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

5.  Central nervous system infections caused by varicella-zoster virus.

Authors:  Francisco J Chamizo; Raúl Gilarranz; Melisa Hernández; Diana Ramos; María José Pena
Journal:  J Neurovirol       Date:  2016-01-14       Impact factor: 3.739

6.  Implementation of the FilmArray ME panel in laboratory routine using a simple sample selection strategy for diagnosis of meningitis and encephalitis.

Authors:  Susanne Pfefferle; Martin Christner; Martin Aepfelbacher; Marc Lütgehetmann; Holger Rohde
Journal:  BMC Infect Dis       Date:  2020-02-22       Impact factor: 3.090

7.  Neurological complications of varicella zoster virus reactivation: Prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid.

Authors:  Tiphaine Lenfant; Anne-Sophie L'Honneur; Brigitte Ranque; Benoit Pilmis; Caroline Charlier; Mathieu Zuber; Jacques Pouchot; Flore Rozenberg; Adrien Michon
Journal:  Brain Behav       Date:  2022-01-18       Impact factor: 2.708

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.